In 2014, the top six best-selling drugs will be biotech products, says EvaluatePharma, a healthcare analysis company. Of the top 100, they say biotech drugs will account for half. Evaulate predicts that the number one drug in five years will be Roche's Avastin, followed by Abbott's Humira, Roche's Rituxan, Wyeth's Enbrel, Sanofi-Aventis' Lantus, and Roche's Herceptin, according to Reuters.